Publication: Future treatments in hypertension: can we meet the unmet needs of patients?
dc.contributor.coauthor | Laffin, Luke | |
dc.contributor.department | School of Medicine | |
dc.contributor.kuauthor | Kanbay, Mehmet | |
dc.contributor.kuauthor | Uçku, Duygu | |
dc.contributor.kuauthor | Tanrıöver, Cem | |
dc.contributor.kuauthor | Çöpür, Sidar | |
dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
dc.date.accessioned | 2025-01-19T10:31:59Z | |
dc.date.issued | 2023 | |
dc.description.abstract | The prevalence of arterial hypertension is approximately 47% in the United States and 55% in Europe. Multiple different medical therapies are used to treat hypertension including diuretics, beta blockers, calcium channel blockers, angiotensin receptor blockers, angiotensin converting enzyme inhibitors, alpha blockers, central acting alpha receptor agonists, neprilysin inhibitors and vasodilators. However, despite the numerous number of medications, the prevalence of hypertension is on the rise, a considerable proportion of the hypertensive population is resistant to these therapeutic modalities and a definitive cure is not possible with the current treatment approaches. Therefore, there is a need for novel therapeutic strategies to provide better treatment and control of hypertension. In this review, our aim is to describe the latest developments in the treatment of hypertension including novel medication classes, gene therapies and RNA-based modalities. | |
dc.description.indexedby | WOS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.volume | 115 | |
dc.identifier.doi | 10.1016/j.ejim.2023.06.008 | |
dc.identifier.eissn | 1879-0828 | |
dc.identifier.issn | 0953-6205 | |
dc.identifier.quartile | Q1 | |
dc.identifier.scopus | 2-s2.0-85163358005 | |
dc.identifier.uri | https://doi.org/10.1016/j.ejim.2023.06.008 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/26337 | |
dc.identifier.wos | 1077165000001 | |
dc.keywords | Hypertension | |
dc.keywords | Hypertension management | |
dc.keywords | Aldosterone synthase inhibitors | |
dc.keywords | Dual endothelin antagonists | |
dc.keywords | Gene-based therapies in hypertension | |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.relation.ispartof | European Journal of Internal Medicine | |
dc.subject | Medicine | |
dc.title | Future treatments in hypertension: can we meet the unmet needs of patients? | |
dc.type | Review | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Kanbay, Mehmet | |
local.contributor.kuauthor | Çöpür, Sidar | |
local.contributor.kuauthor | Tanrıöver, Cem | |
local.contributor.kuauthor | Uçku, Duygu | |
local.publication.orgunit1 | SCHOOL OF MEDICINE | |
local.publication.orgunit2 | School of Medicine | |
relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |